Reading ANIK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANIK free→Reading ANIK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ANIK free→QuarterlyIQ Insights · ANIK
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the “Board”) of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company’s 2026 annual meeting of stockholders…
of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 26, 2026, the Company and Mr. Colleran entered into a Transitional Services and General Release of Claims Agreement (the “Transition Agreement”). Pursuant to the Transition Agreement, Mr. Colleran will continue to be employed by the Company as its Executive Vice President, General Counsel and Corporate Secretary through May 1, 2026 (the…
Results of Operations and Financial Condition. On January 8, 2026, Anika Therapeutics, Inc. (the “Company”) issued a press release and reaffirmed guidance for the year ended on December 31, 2025. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. As previously announced, the Company expects 2025 revenue ranges by channel as follows: • Commercial Channel, unchanged, of $47 to $49.5 million, up 12% to 18% year over year. • OEM Channel, unchanged, of $…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. President and Chief Executive Officer Transition On January 8, 2026, the Company announced that, effective February 1, 2026 (the “Transition Date”), Cheryl R. Blanchard will transition from her role as President and Chief Executive Officer. Dr. Blanchard will transition into the role of Executive Chair of the Company’s Board of Directors (“Board”)…
Results of Operations and Financial Condition. The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such fil…
Results of Operations and Financial Condition. The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such fil…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan On April 21, 2025, the board of directors, or the Board, of Anika Therapeutics, Inc., or the Company, adopted and approved, subject to stockholder approval, an amendment, or the Amendment, to the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan as previously amended, or the 2…
Results of Operations and Financial Condition. The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such fil…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 4, 2025, Anika Therapeutics, Inc. (the “Company”) announced the departure of Anne Nunes, Chief Operations Officer, effective April 25, 2025. In connection with her departure, Ms. Nunes will receive severance benefits in accordance with her Executive Retention Agreement, which is filed as Exhibit 10.14 to the Company’s Form 10-K, filed on M…
Results of Operations and Financial Condition. The following information, including the exhibit attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such fil…
Completion of Acquisition or Disposition of Assets. On March 7, 2025 (the “Closing Date”), Anika Therapeutics, Inc., a Delaware corporation (the “Company”), completed its sale of all of the outstanding equity interests of Parcus Medical, LLC, a Wisconsin limited liability company and former wholly-owned subsidiary of the Company (“Parcus”), to Medacta Americas Manufacturing, Inc., a Delaware corporation (“Buyer”), pursuant to the terms and conditions of a Membership Interest Purchase Agreemen…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.